W
William N. Washburn
Researcher at Bristol-Myers Squibb
Publications - 69
Citations - 3160
William N. Washburn is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Diabetes mellitus & Dapagliflozin. The author has an hindex of 23, co-authored 69 publications receiving 2994 citations.
Papers
More filters
Journal ArticleDOI
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Wei Meng,Bruce A. Ellsworth,Alexandra A. Nirschl,P.J. McCann,Manorama Patel,Ravindar N. Girotra,Gang Wu,Philip M. Sher,Eamonn P. Morrison,Scott A. Biller,Robert Zahler,Prashant P. Deshpande,Annie Pullockaran,Deborah Hagan,Nathan Morgan,Joseph R. Taylor,Mary T. Obermeier,William G. Humphreys,Ashish Khanna,Lorell Discenza,James G. Robertson,Aiying Wang,Songping Han,John R. Wetterau,Evan B. Janovitz,Oliver P. Flint,Jean M. Whaley,William N. Washburn +27 more
TL;DR: The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats.
Journal ArticleDOI
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Songping Han,Deborah Hagan,Joseph R. Taylor,Li Xin,Wei Meng,Scott A. Biller,John R. Wetterau,William N. Washburn,Jean M. Whaley +8 more
TL;DR: In vivo and in vitro data suggest that dapagliflozin has the potential to be an efficacious treatment for type 2 diabetes.
Patent
C-aryl glucoside SGLT2 inhibitors and method
TL;DR: In this article, an SGLT2 inhibiting compound is provided having the formula having the chemical structure, and a method is also provided for treating diabetes and related diseases employing an sGLT 2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Patent
C-aryl glucoside SGLT2 inhibitors
TL;DR: In this paper, a method for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Patent
CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS
William N. Washburn,Ravindar N. Girotra,Philip M. Sher,Amarendra B. Mikkilineni,Poss Kathleen M,Arvind Mathur,Ashvinikumar V. Gavai,Gregory S. Bisacchi +7 more
TL;DR: In this paper, the authors present compounds of the formula "STR1" and pharmaceutically acceptable salts thereof, which are beta-three adrenergic receptor agonists and are useful in the treatment of diabetes, obesity and gastrointestinal diseases.